BioNTech's Founders Exit Stage Left as the Company's Post-COVID Identity Takes Shape
Published on 08/06/2026 at 05:21 | Redaktion boerse-global.de
The numbers were grim, but the news that truly reshaped BioNTech's narrative this week had less to do with the income statement and more with the names on the office doors. Ugur Sahin and Özlem Türeci, the immunologist couple who built the Mainz-based company into a global force during the pandemic, confirmed they are leaving the business entirely by year-end to establish a new mRNA venture — one in which BioNTech will retain a minority stake.
Their departure coincides with the appointment of Guido Oelkers, formerly chief executive of Swedish rare-disease specialist Sobi, as the incoming CEO. Oelkers is slated to take the helm no later than February 1, 2027, and will inherit a company in the middle of a delicate transition: COVID-19 vaccine revenue is collapsing, the oncology pipeline is still years from commercialization, and investors are watching to see whether the firm's substantial cash reserves can bridge the gap.
A Quarter That Missed on Every Front
The second-quarter figures released Wednesday painted a stark picture. Revenue came in at €105.6 million, a 59.5 percent plunge from the €260.8 million recorded in the same period last year. The IFRS net loss widened to €820.8 million, or €3.24 per diluted share — more than double the €1.60 loss per share a year earlier. Analysts had braced for weakness, but not this much: the adjusted loss per share of €2.22 came in 18 cents above the consensus estimate of €2.04, while revenue fell well short of the €162.59 million the market had penciled in.
Management attributed the shortfall to two factors: persistently weak demand for COVID-19 vaccines and deferred milestone payments from partnership agreements. The company did offer a sliver of good news on the product front — the European Commission granted approval in late July for an XFG-adapted COVID vaccine developed with Pfizer for the 2026/2027 respiratory season — but that does little to alter the structural decline in the core business.
Should investors sell immediately? Or is it worth buying BioNTech?
Guidance Trimmed, R&D Budget Tightened
The weak quarter forced BioNTech to slash its full-year 2026 revenue forecast to a range of €1.6 billion to €1.9 billion, down from the €2.0 billion to €2.3 billion previously communicated. Research and development spending guidance was also revised downward, a signal that management expects the soft patch to persist rather than resolve quickly.
The company's balance sheet, however, remains a formidable buffer. As of June 30, BioNTech held €16.63 billion in cash and marketable securities — a war chest that provides considerable runway as the company pivots its focus toward oncology. Operating cash flow stayed positive at €10.5 million, though that marks a sharp decline from the €146.5 million generated in the year-ago quarter.
The Oncology Bet Takes Center Stage
With the vaccine franchise fading, the company's future now rests on its cancer pipeline. BioNTech says it expects to have 15 Phase 3 studies underway by the end of 2026, with three late-stage readouts anticipated across immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. Together with partner DualityBio, the company also plans to file for approval of its antibody-drug conjugate candidate Trastuzumab Pamirtecan in endometrial carcinoma during the current year.
The strategic pivot comes with notable insider activity. Sierk Poetting, the company's corporate development chief, reduced his direct stake by 11 percent through a pre-arranged trading plan, a sale worth approximately $5.5 million. Institutional investor Carmignac Gestion also trimmed its position in BioNTech's American Depositary Receipts.
Analysts Hold Their Ground, With Caveats
Despite the disappointing print, the analyst community has not abandoned the stock. Jefferies reaffirmed its buy rating following the earnings release and guidance cut, as did Clear Street, though the latter trimmed its price target to $167. Evercore ISI maintained its "Outperform" rating while lowering its target from $140 to $130, and Berenberg's Harry Gillis reduced his price objective from $140 to $132 while keeping a "Buy" recommendation. Gillis argued that the lowered expectations for the COVID vaccine business were hardly surprising, and that the product pipeline remains undervalued.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Market Reaction: Measured, Not Panicked
The share price response was notably muted given the scale of the news. On Wednesday, the stock closed at €79.70 in Frankfurt, up 1.01 percent, though the secondary listing traded at €78.65, down 0.44 percent. The shares sit roughly a quarter below their 52-week high of €105.80 reached in January, and trade almost exactly at their 50-day moving average — a sign that investors are reserving judgment until the contours of the new leadership's strategy become clearer. On a monthly basis, the stock is down 4.26 percent, and it remains 6.62 percent below its 200-day average, reflecting the lingering overhang of the COVID revenue decline.
The coming months will test whether Oelkers — tasked with revitalizing the US business and sharpening the company's focus on revenue and profitability — can convince the market that BioNTech's oncology ambitions can eventually replace the windfall that made it a household name.
Ad
BioNTech Stock: New Analysis - 6 August
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
